Faron Pharmaceuticals raises £7.48 million to advance Clevegen®
Abraham Darwyne
Company News - 3 min
11:34, 8th November 2019

Faron Pharmaceuticals (FARN) FOLLOW, on Friday finished a £7.48 million private placing to further the clinical development of Clevegen®.

Dr Markku Jalkanen, CEO of Faron, commented: "This financing will allow us to further progress our clinical programme on Clevegen with a view to clarifying its full potential, either alone or in combination with existing cancer treatments.”

Faron’s MATINS trial showed that Clevegen® promoted immune activation in patients, potentially making it a new and effective macrophage immune checkpoint drug for cancer patients.

Dr. Jalkanen said: “This is very important as many, if not all, cancer patients have reduced immune capacity to defend them against cancer spread and may potentially be focal information in terms of specifying our goals for the ongoing partnering discussions."

Shares in Faron were trading 10.47% higher at 237.5p after the fundraise

Shares in Faron have risen by about 350% year to date.

3,935,500 shares were placed at 190p, representing about 10% of Faron’s issued share capital before the placing.

Faron told investors that the proceeds are expected to provide twelve months of working capital.

The company is to advance Clevegen, initiating the cohort expansion of the MATINS trial in colorectal cancer, eventually sharing the data with the US FDA to discuss a biologics licence application.

It is also having a face-to-face meeting with the FDA in early December to discuss Traumakine, its phase III treatment for acute respiratory distress.

Faron also welcomed the significant number of new Nordic shareholders after the placing, after Swedish firm Carnegie Investment Bank AB acted as financial adviser and bookrunner.

Follow News & Updates from Faron Pharmaceuticals here: FOLLOW

Disclaimer & Declaration of Interest

The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.

Comments
info
Login or register to post comments

Recent Articles
Watchlist